WO2017025894A1 - Extended release capecitabine tablets - Google Patents

Extended release capecitabine tablets Download PDF

Info

Publication number
WO2017025894A1
WO2017025894A1 PCT/IB2016/054780 IB2016054780W WO2017025894A1 WO 2017025894 A1 WO2017025894 A1 WO 2017025894A1 IB 2016054780 W IB2016054780 W IB 2016054780W WO 2017025894 A1 WO2017025894 A1 WO 2017025894A1
Authority
WO
WIPO (PCT)
Prior art keywords
capecitabine
tablets
amount
hours
extended release
Prior art date
Application number
PCT/IB2016/054780
Other languages
French (fr)
Inventor
Ashish Sehgal
Manishkumar CHAUHAN
Manishkumar PATEL
Kavan PANDYA
Rushabh BHIMANI
Original Assignee
Intas Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intas Pharmaceuticals Ltd. filed Critical Intas Pharmaceuticals Ltd.
Publication of WO2017025894A1 publication Critical patent/WO2017025894A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • WO2013030602 discloses extended release pharmaceutical composition for oral administration comprising substantially amorphous Capecitabine or an analog thereof and optionally extended release component, wherein the extended release component is present in an amount of less than 200% w/w, relative to the total weight of the Capecitabine or analog thereof.
  • Present invention provides extended release tablets comprising Capecitabine, wherein the dissolution of Capecitabine from the said tablets is extended up to at least 12 hours.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to extended release tablets comprising Capecitabine, wherein the dissolution of Capecitabine from the said tablets is extended up to at least 12 hours. Further, the present invention discloses process for the preparation of the said tablets.

Description

EXTENDED RELEASE CAPECITABINE TABLETS
RELATED APPLICATIONS
This application is related to Indian Provisional Application 3008/MUM/2015 filed 10th August, 2015 and is incorporated herein in its entirety.
FIELD OF THE INVENTION
The present invention relates to extended release tablets comprising Capecitabine, wherein the dissolution of Capecitabine from the said tablets is extended up to at least 12 hours. Further, the present invention discloses process for the preparation of the said tablets.
BACKGROUND OF THE INVENTION
Capecitabine is a fluoropyrimidine carbamate having antineoplastic activity. It is an orally administered systemic prodrug of 5'-deoxy-5-fluorouridine (5'-DFUR) which is converted to fluorouracil. Molecular formula of Capecitabine is C15H22FN3O6 and the molecular weight is 359.35 and has following chemical structure:
Figure imgf000002_0001
(Capecitabine)
US4966891 and US5472949 discloses Fluorocytidine derivatives and N4 - (substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine compounds respectively which cover Capecitabine and methods of using same. Capecitabine is marketed as immediate release tablet comprising 150 or 500 mg Capecitabine for oral administration under trade name XELODA® by Roche. The inactive ingredients in XELODA include: anhydrous lactose, croscarmellose sodium, hydroxypropyl methylcellulose, microcrystalline cellulose, magnesium stearate and purified water. The peach or light peach film coating contains hydroxypropyl methylcellulose, talc, titanium dioxide, and synthetic yellow and red iron oxides. Capecitabine is indicated for colon cancer, metastatic colorectal cancer and metastatic breast cancer as monotherapy or combination therapy.
Recommended standard starting dose of Capecitabine is 1250 mg/m administered orally twice daily (morning and evening; equivalent to 2500 mg/m total daily dose) for 2 weeks followed by a 1-week rest period given as 3-week cycles. In combination with docetaxel, the recommended dose of Capecitabine is 1250 mg/m twice daily for 2 weeks followed by a 1-week rest period, combined with docetaxel at 75 mg/m as a 1-hour intravenous infusion every 3 weeks. Capecitabine Tablets should be swallowed with water within 30 minutes after the end of a meal.
Currently available immediate release (IR) composition of Capecitabine has Tmax of approximately 1.5 hours and Ti/2 of 0.75 hours. Further the available composition does not maintain constant plasma concentration i.e difficult to achieve steady state concentration.
After administration of currently available IR composition of Capecitabine, the plasma concentration of a Capecitabine reaches below minimum effective concentration after approximately 6 hours, which result in no therapeutic effect between 6 to 12 hours after administration of the dose (figure 1).
Capecitabine has high therapeutic value for the treatment of cancer. IR tablet of Capecitabine may lead to severe gastrointestinal side effects. Till date, several approaches are reported to overcome the problem associated with IR composition. WO2013030602 discloses extended release pharmaceutical composition for oral administration comprising substantially amorphous Capecitabine or an analog thereof and optionally extended release component, wherein the extended release component is present in an amount of less than 200% w/w, relative to the total weight of the Capecitabine or analog thereof.
WO2006110800 discloses a multiparticulate modified release composition comprising Capecitabine, wherein, following oral delivery, the composition delivers Capecitabine in a pulsatile manner.
US20070122481 discloses a multiparticulate modified release composition comprising a Capecitabine, wherein, following oral delivery, the composition delivers the Capecitabine in a pulsatile manner. However, still there is need to develop Capecitabine composition which overcomes problems associated with currently available IR tablet, and releases the drug from the composition up to at least 12 hours after administration, which in-turn shall provide and maintain effective plasma concentration of Capecitabine approximately for 12 hours.
OBJECT OF THE INVENTION
It is therefore, object of the invention is to provide extended release tablets comprising Capecitabine, wherein the dissolution of Capecitabine from the said tablets is extended up to at least 12 hours.
Another object of the present invention is to provide process for the preparation of extended release tablets comprising Capecitabine, wherein the dissolution of Capecitabine from the said tablets is extended up to at least 12 hours. Another object of the present invention is to provide extended release tablets comprising Capecitabine, wherein the dissolution of Capecitabine from the said tablets is 15 to 35% after 1 hour, 40 to 60% after 4 hours, 60 to 80% after 8 hours and not less than (NLT) 85% of the total amount of Capecitabine released after 12 hours.
Another object of the present invention is to provide process for the preparation of the extended release tablets comprising Capecitabine, wherein the dissolution of Capecitabine from the said tablets is 15 to 35% after 1 hour, 40 to 60% after 4 hours, 60 to 80% after 8 hours and not less than (NLT) 85% of the total amount of Capecitabine released after 12 hours.
Another object of the present invention is to provide extended release tablets comprising Capecitabine, wherein the release is controlled by modified release matrix material.
Another object of the present invention is to provide extended release tablets comprising Capecitabine, wherein the release is controlled by modified release coating material.
Another object of the present invention is to provide extended release tablets comprising Capecitabine, wherein the release is controlled by modified release coating on multi-particulates comprising Capecitabine. Another object of the present invention is to provide extended release tablets comprising Capecitabine suitable for twice daily dosage regime, wherein dissolution of Capecitabine from the said tablets is extended up to at least 12 hours. Another object of the present invention is to provide extended release tablets comprising Capecitabine which would release the drug from the said tablets up to at least 12 hours after administration. Another object of the present invention is to provide extended release tablets comprising Capecitabine, which shall provide and maintain effective plasma concentration of Capecitabine approximately for 12 hours after administration.
Another object of the present invention is to provide extended release tablets comprising Capecitabine wherein the tablets comprises Capecitabine ranging from 150 to 750 mg, wherein dissolution of Capecitabine from the said tablets is extended up to at least 12 hours.
Another object of the present invention is to provide extended release tablets comprising a) Capecitabine in an amount of 55 to 80 % w/w of the total weight of the tablet b) diluent in an amount of 1 to 15 % w/w of the total weight of the tablet c) modified release matrix material in an amount of 5 to 40 % w/w of the total weight of the tablet d) binder in an amount of 2 to 4 % w/w of the total weight of the tablet e) lubricant in an amount of 0.5 to 2 % w/w of the total weight of the tablet.
Another object of the present invention is to provide extended release tablets comprising Capecitabine, wherein the release is controlled by modified release matrix material or modified release coating material or modified release coating on multi-particulates which would release the drug from the said tablets up to 24 hours after administration.
SUMMARY OF THE INVENTION Present invention provides extended release tablets comprising Capecitabine, wherein the dissolution of Capecitabine from the said tablets is extended up to at least 12 hours. Further the present invention provides extended release tablets comprising Capecitabine, wherein the release from the tablets is controlled by modified release matrix material, modified release coating material or modified release coating on multi-particulates. Further the present invention provides extended release tablets comprising Capecitabine suitable for twice daily dosage regime which releases the drug from the said tablets up to at least 12 hours after administration. Further the present invention provides extended release tablets comprising Capecitabine ranging from 150 to 750 mg. BRIEF DESCRIPTION OF THE FIGURES
Figure 1 shows plasma cone, of Capecitabine immediate release tablet.
Figure 2 shows dissolution profile of Capecitabine extended release tablets 500 mg prepared according to example 2.
Figure 3 shows dissolution profile of Capecitabine extended release tablets 150 mg prepared according to example 3.
Figure 4 shows dissolution profile of Capecitabine extended release tablets 500 mg prepared according to example 5.
Figure 5 shows dissolution profile of Capecitabine extended release tablets 500 mg prepared according to example 7.
DETAILED DESCRIPTION OF THE INVENTION
Present invention provides extended release tablets comprising Capecitabine, wherein the dissolution of Capecitabine from the said tablets is extended up to at least 12 hours.
In another embodiment, the present invention provides process for the preparation of extended release tablets comprising Capecitabine, wherein the dissolution of Capecitabine from the said tablets is extended up to at least 12 hours. In another embodiment, the present invention provides extended release tablets comprising Capecitabine, wherein the dissolution of Capecitabine from the said tablets is 15 to 35% after 1 hour, 40 to 60% after 4 hours, 60 to 80% after 8 hours and NLT 85% of the total amount of Capecitabine is released after 12 hours.
In another embodiment, the present invention provides process for the preparation of the extended release tablets comprising Capecitabine, wherein the dissolution of Capecitabine from the said tablets is 15 to 35% after 1 hour, 40 to 60% after 4 hours, 60 to 80% after 8 hours and NLT 85% of the total amount of Capecitabine is released after 12 hours.
In another embodiment, the present invention provides extended release tablets comprising Capecitabine which would release the drug from the said tablets up to at least 12 hours after administration.
In another embodiment, the present invention provides extended release tablets comprising Capecitabine suitable for twice daily administration which shall provide and maintain effective plasma concentration of Capecitabine approximately for 12 hours after administration.
In another embodiment, the present invention provides extended release tablets comprising Capecitabine, wherein the dissolution of Capecitabine from the said tablets is extended up to at least 12 hours, wherein the release is controlled by modified release matrix material or modified release coating material or modified release coating on multi-particulates and process for preparation thereof.
In another embodiment, the present invention provides extended release tablets comprising a) Capecitabine in an amount of 55 to 80 % w/w of the total weight of the tablet b) diluent in an amount of 1 to 15 % w/w of the total weight of the tablet c) modified release matrix material in an amount of 5 to 40 % w/w of the total weight of the tablet d) binder in an amount of 2 to 4 % w/w of the total weight of the tablet e) lubricant in an amount of 0.5 to 2 % w/w of the total weight of the tablet.
For the purpose of this specification, the term "extended release" means a release of drug for a longer duration of time i.e. not immediate release.
For the purpose of this specification, the term "modified release coating material" means coating material applied onto the core tablet comprising Capecitabine which controls the release of Capecitabine form the tablet. Modified release coating material is interchangeable with functional coat used in the examples. For the purpose of this specification, the term "multi-particulates" means a plurality of spheres, granules or pellets, wherein Capecitabine is present into the core of the spheres, granules or pellets or wherein inert core of the spheres, granules or pellets are coated with a layer comprising Capecitabine. According to the present invention, extended release tablets comprising Capecitabine, wherein the release of Capecitabine is controlled by modified release matrix material or modified release coating material or modified release coating on multi-particulates which further comprises suitable excipients. According to the present invention, suitable excipients may include, but not limited to binder, diluent, lubricant, glidant, and like thereof.
According to the present invention, binder may include, but not limited to acacia, carbomer, carboxymethylcellulose, cellulose microcrystalline, copovidone, gelatin, guar gum, hydroxypropyl cellulose, low -substituted hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate succinate, methyl cellulose, ethyl cellulose, polyethylene oxide, povidone, starch, pregelatinized starch, ammonio methacrylate copolymer and the like, or mixtures thereof. According to the present invention, diluent may include, but not limited to lactose anhydrous, lactose monohydrate, spray dried lactose, dicalcium phosphate, calcium phosphate tribasic, calcium carbonate, calcium sulfate, starch, corn starch, potato starch, wheat starch, pregelatinized starch, microcrystalline cellulose, silicified microcrystalline cellulose, cellulose microcrystalline powdered and the like, or mixtures thereof.
According to the present invention, lubricant may include, but not limited to calcium stearate, glyceryl behenate, magnesium stearate, mineral oil light, polyethylene glycol, castor oil, sodium stearyl fumarate, starch, stearic acid, talc, hydrogenated vegetable oil, zinc stearate, sodium benzoate and the like, or mixtures thereof.
According to the present invention, glidant may include, but not limited to calcium silicate, magnesium silicate, colloidal silicon dioxide, talc and the like, or mixtures thereof.
In another embodiment, the present invention provides extended release tablets comprising Capecitabine, wherein dissolution of Capecitabine from the said tablets is extended up to at least 12 hours.
In another embodiment, the present invention provides extended release tablets comprising Capecitabine, wherein the release is controlled by modified release matrix material or modified release coating material or modified release coating on multi-particulates which further comprises suitable excipients, wherein the dissolution of Capecitabine from the said tablets is 15 to 35% after 1 hour, 40 to 60% after 4 hours, 60 to 80% after 8 hours and NLT 85% of the total amount of Capecitabine is released after 12 hours.
In another embodiment, the present invention provides extended release tablets comprising: a) Capecitabine in an amount of 150 to 750 mg per tablet, b) lactose in an amount of 5 to 35 mg per tablet, c) microcrystalline cellulose in an amount of 5 to 50 mg per tablet, d) Hydroxypropyl methylcellulose in an amount of 15 to 100 mg per tablet, e) binder in an amount of 5 to 30 mg per tablet and f) lubricant in an amount of 2 to 15 mg per tablet; wherein, the dissolution of Capecitabine from the tablets is 15 to 35% after 1 hour, 40 to 60% after 4 hours, 60 to 80% after 8 hours and not less than (NLT) 85% of the total amount of Capecitabine released after 12 hours.
Method of dissolution study is well known in the art. Preferably dissolution study can be carried out in type II or type I dissolution apparatus USP, using suitable buffer or purified water as dissolution medium at 37°C and 50/75/100 RPM.
In another embodiment, the present invention provides extended release tablets comprising Capecitabine, wherein dissolution of Capecitabine from the said tablets is extended up to at least 12 hours after administration, wherein the tablets comprises Capecitabine ranging from 150 to 750 mg.
In another embodiment, the present invention provides extended release tablets comprising Capecitabine, wherein dissolution of Capecitabine from the said tablets is extended up to at least 12 hours after administration, wherein the tablets comprises crystalline or amorphous form of Capecitabine.
In another embodiment, the present invention provides extended release tablets comprising Capecitabine, wherein the release is controlled by modified release matrix material. According to the present invention modified release matrix material may include hydrophilic matrix material or hydrophobic matrix material or mixture thereof.
According to the present invention modified release matrix material may include, but not limited to hydroxypropyl methylcellulose (HPMC) with different viscosity grade; for example, HPMC K4M, HPMC K100M, HPMC K100LV, hydroxypropylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropyl ethylcellulose, methylcellulose, ethylcellulose, carboxyethylcellulose, carboxymethyl hydroxyethylcellulose, carbomer, sodium carboxymethylcellulose, polyvinylpyrrolidone, hydrophobic polymers, waxes, fats, long-chained fatty acids, fatty alcohols or corresponding esters or ethers or their mixtures, and the like, or mixtures thereof.
In another embodiment, the present invention provides extended release tablets comprising Capecitabine, wherein the release is controlled by modified release coating material.
According to the present invention modified release coating material may include pH-dependent coating material or pH-independent coating material or mixture thereof.
According to the present invention modified release coating material may include, but not limited to alkyl celluloses such as, e.g. ethyl cellulose, or cellulose esters, such as, e.g. cellulose acetate, cellulose acetate phthalate, hydroxylpropyl methyl cellulose phthalate, poly vinyl acetate phthalate, polymethacrylate, copolymer of ethyl acrylate and methyl methacrylate, ammonio methacrylate copolymers, polyacrylic acid and polyacrylate and methacrylate copolymers, shellac, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl pyrrolidone, and the like, or mixtures thereof. In another embodiment, the present invention provides process for the preparation of extended release tablets comprising Capecitabine, wherein the release is controlled by modified release matrix material comprises steps of: a) mixing Capecitabine, diluent(s) and modified release matrix material to form blend, b) Preparing binder solution by dissolving binder into purified water, c) granulating the blend obtained in step a) using binder solution, d) mixing lubricant and / or glidant and optionally modified release matrix materials with granules obtained in step c), e) compressing the blended granules obtained in step d) to form tablets and f) optionally, film coating the tablets obtained in step e.
According to the present invention modified release coating on multiparticulates, wherein the modified release coating material may include, but not limited to alkyl celluloses such as, e.g. ethyl cellulose, or cellulose esters, such as, e.g. cellulose acetate, cellulose acetate phthalate, hydroxylpropyl methyl cellulose phthalate, poly vinyl acetate phthalate, polymethacrylate, copolymer of ethyl acrylate and methyl methacrylate, ammonio methacrylate copolymers, polyacrylic acid and polyacrylate and methacrylate copolymers, shellac, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl pyrrolidone, and the like, or mixtures thereof.
In another embodiment, the present invention provides process for the preparation of extended release tablets comprising Capecitabine, wherein the release is controlled by modified release coating material comprises steps of: a) mixing Capecitabine and diluent(s), b) granulating the blend obtained in step a) using binder solution, c) mixing lubricant with granules obtained in step b), d) compressing the blended granules obtained in step c) to form tablets and e) applying modified release coat on to the tablet obtained in step d). In another embodiment, the present invention provides extended release tablets comprising Capecitabine, wherein the release is controlled by modified release coating on multi-particulates. In another embodiment, the present invention provides extended release tablets comprising Capecitabine, wherein the release is controlled by modified release matrix material or modified release coating material or modified release coating on multi-particulates which would release the drug from the said tablets up to 24 hours after administration.
EXAMPLES
The present invention has been described by way of example only, and it is to be recognized that modifications thereto falling within the scope and spirit of appended claims, and which would be obvious to a person skilled in the art based upon the disclosure herein, are also considered to be within the scope of this invention.
EXAMPLE 1: Extended release tablets comprising Capecitabine wherein release is controlled by hydrophilic modified release matrix material
Sr. No. I nmvilic lis ol
1 ahlel
1 Capecitabine 55% to 80%
2 Diluent(s) 0% to 15%
3 Hydrophilic modified release matrix 5% to 40%
material(s)
4 Binder 2% to 4%
5 Granulating fluid q.s.
6 Glidant (s) 0.5% to 1.5%
7 Lubricant(s) 0.5% to 1.5% Film coat 2% to 4%
Process:
1. Capecitabine, diluent(s) and modified release matrix material(s) were admixed together to form uniform blend.
2. The blended material of step 1 was granulated using binder solution.
3. Modified release matrix material(s), glidant(s) and / or lubricant(s) were mixed with granules obtained in step 2.
4. Blended granules of step 3 were compressed to form tablets.
5. Optionally film coating the tablets obtained in step 4.
EXAMPLE 2: Extended release tablets comprising Capecitabine wherein release is controlled by hydrophilic modified release matrix material
Sr. No. I ii LMvdicni s Ms/tablet
Cor e Tablets
1 Capi icitabine 500.00
2 Mia Ocrystalline cellulose 26.00
3 Hyd roxypropyl Methylcellulose 70.00
(HP! VIC K4M )
4 Hyd roxypropyl Methylcellulose 6 cps 20.00
5 Puri ied water q.s
6 Hyd roxypropyl Methylcellulose 70.00
(HP! VIC K4M)
7 Talc 7.00
8 Mag nesium stearate 7.00
9 Film coat 20
Tota 1 weight of coated tablet 720 1. Capecitabine, microcrystalline cellulose, hydroxypropyl methylcellulose (HPMC K4M) were admixed properly to obtain uniform blend.
2. Hydroxypropyl methylcellulose 6 cps was dissolved in purified water and used to granulate the blend of step 1 to obtain granule, optionally sifting the granules.
3. Hydroxypropyl methylcellulose (HPMC K4M) and Talc were sifted and mixed properly with granules of step 2.
4. Magnesium stearate was mixed properly with materials of step 3.
5. Lubricated blend of step 4 was compressed to form tablet.
6. Film coat was applied on compressed tablets of step 5.
EXAMPLE 3: Extended release tablets comprising Capecitabine wherein release is controlled by hydrophilic modified release matrix material
Sr. Mo. liiLiivdicnis M n/lahlel
Core l ^ablets
1 Capec] tabine 150.00
2 Lactos e anhydrous 7.500
3 Microc crystalline cellulose 10.50
4 Hydro xypropyl Methylcellulose 6 cps 7.50
5 Purifie d water q.s
6 Hydro xypropyl Methylcellulose 22.50
(HPM< 2 K4M CR)
7 Magne sium stearate 3.00
8 Film c oat 6.00
Total \ veight of coated tablet 207 Process:
1. Capecitabine, lactose anhydrous, microcrystalline cellulose and part of Hydroxypropyl methylcellulose 6 cps were admixed properly to obtain uniform blend.
2. Remaining part of hydroxypropyl methylcellulose 6 cps was dissolved in purified water and was used to granulate the blend of step 1 to obtain granules.
3. Hydroxypropyl methylcellulose (HPMC K4M CR) and magnesium stearate were sifted and mixed properly with granules of step 2.
4. Lubricated blend of step 3 was compressed to form tablet.
5. Film coat was applied on compressed tablets of step 4.
EXAMPLE 4: Extended release tablets comprising Capecitabine wherein release is controlled by Hydrophobic modified release matrix material
Sr. I ngred ient s %w/w ii
Tahlcl
Capecitabine 55% to 80%
Diluent(s) 0% to 15%
Hydrophobic modified release matrix 5% to 15% material(s)
Granulating fluid q.s.
Glidant (s) 0.5% to 1.5%
Lubricant(s) 0.5% to 1.5%
Film coat 2% to 4%
Process:
1. Capecitabine and diluent(s) were admixed together to form uniform blend.
2. Hydrophobic modified release matrix material(s) was dissolved in
Granulating fluid. 3. The blended material of step 1 was granulated using solution obtained in step 2.
4. Glidant(s) and / or lubricant(s) were mixed with granules obtained in step 3.
5. Blended granules of step 4 were compressed to form tablets.
6. Optionally film coating the tablets obtained in step 4.
EXAMPLE 5: Extended release tablets comprising Capecitabine wherein release is controlled by Hydrophobic modified release matrix material
Sr. No. l iiLiivilienl s Mti/lahlcl
Con e Tablet
1 Cape ^citabine 500.00
2 Mici •ocrystalline cellulose 66.00
3 Ethy 1 cellulose 80.00
4 Etha nol q.s
5 Talc 7.00
6 Mag nesium stearate 7.00
7 Film coat 20
Tota 1 weight of coated tablet 680
Process:
1. Capecitabine and microcrystalline cellulose were admixed together to form uniform blend.
2. Ethyl cellulose was dissolved in ethanol and used to granulate the materials of step 1.
3. The blended material of step 1 was granulated using solution obtained in step 2.
4. Talc and magnesium stearate were sifted through appropriate sieve and mixed properly with sized granules. 5. Blended granules of step 4 were compressed to form tablets.
6. Film coat was applied on compressed tablets of step 5.
EXAMPLE 6: Extended release tablets comprising Capecitabine wherein release is controlled by modified release coating material
Sr. No. In mvdienis w lw ol 1 ahlel
Core
1 Cape citabine 50% to80%
2 Dilue ;nt(s) 15% to 50%
3 Bind sr(s) 1% to 3%
4 Gran ulating fluid q.s.
5 lubri< :ant(s) 0.5 % to 2%
Func tional coat
7 Ethyl cellulose 3% to 7%
8 Hydr oxypropyl Methylcellulose E6 0.1% to 1%
9 Talc 0.1% to 1%
10 Purif ied water q.s
Process:
1. Capecitabine and diluent(s) were sifted and mixed.
2. Binder(s) was dissolved in granulating fluid.
3. The blended material of step 1 was granulated using solution of step 2.
4. The granules of step 3 were dried.
5. Lubricant(s) was mixed with granules of step 4.
6. Lubricated blend of step 5 was compressed to form tablet.
7. Functional film coat was applied on tablets of step 6.
EXAMPLE 7: Extended release tablets comprising Capecitabine wherein release is controlled by modified release coating material Sr. No. I ngred ient s Mg/tab
Core
1 Cape citabine 500.00
2 Lactc )se monohydrate 130.00
3 Micr ocrystalline cellulose 50.00
4 Hydr oxypropyl Methylcellulose E5 14.00
5 Purif ied water q.s
6 Magi lesium stearate 6.00
Func :tional coat
7 Ethyl cellulose 35.00
8 Hydr oxypropyl Methylcellulose E6 3.00
9 Talc 2.00
10 Purif ied water q.s
Process:
1. Capecitabine, lactose monohydrate, microcrystalline cellulose were sifted through appropriate sieve.
2. Materials of step 1 were placed in granulator and dry mixed properly.
3. Hydroxypropyl methylcellulose (HPMC E5) was dissolved in Purified water and used to granulate the materials of step 2.
4. Wet mass was dried in rapid dryer.
5. Dried granules were passed through appropriate sieve.
6. Magnesium stearate was passed through appropriate sieve and mixed with sized granules for 5 minutes.
7. Lubricated blend was compressed using appropriate tooling.
8. Tablets obtained of step 7 were coated using coating solution prepared from ethyl cellulose, hydroxypropyl methylcellulose E6, talc and purified water. EXAMPLE 8: Extended release tablets comprising Capecitabine wherein release is controlled by hydrophilic modified release matrix material
Sr. No. lii LMvd ienl s M -i/laMcl
Core ' rablets
1 Capec itabine 500.00
2 Lactos e anhydrous 25.00
3 Micro crystalline cellulose 35.00
4 Hydro xypropyl Methylcellulose 6 cps 25.00
5 Purifk ;d water q.s
Hydro xypropyl Methylcellulose
75.00
(HPM C K4M CR)
7 Magm isium stearate 10.00
8 Film c oat 20.00
Total ^ weight of coated tablet 690 Process:
1. Capecitabine, lactose anhydrous, microcrystalline cellulose and part of Hydroxypropyl methylcellulose 6 cps were admixed properly to obtain uniform blend.
2. Remaining part of hydroxypropyl methylcellulose 6 cps was dissolved in purified water and was used to granulate the blend of step 1 to obtain granules.
3. Hydroxypropyl methylcellulose (HPMC K4M CR) and magnesium stearate were sifted and mixed properly with granules of step 2.
4. Lubricated blend of step 3 was compressed to form tablet.
5. Film coat was applied on compressed tablets of step 4.
Dissolution study results: The dissolution study of the tablets prepared according to examples 2, 3, 5, and 7 were carried by in type II dissolution apparatus USP, using 900 ml purified water as dissolution medium at 37°C and 50 RPM.
The obtained dissolution study results are tabulated below:
Figure imgf000022_0001
Thus, extended release tablets comprising Capecitabine suitable for twice daily administration can be prepared according to the present invention wherein dissolution of Capecitabine from the said tablets is extended up to at least 12 hours.

Claims

We claim:
Extended release tablets comprising Capecitabine, wherein the dissolution of Capecitabine from the tablets is extended up to at least 12 hours.
The extended release tablets according to claim 1, wherein the dissolution of Capecitabine from the tablets is 15 to 35% after 1 hour, 40 to 60% after 4 hours, 60 to 80% after 8 hours and not less than (NLT) 85% of the total amount of Capecitabine released after 12 hours.
The extended release tablets according to claim 1 , wherein the release controlled by modified release matrix material.
The extended release tablets according to claim 3, wherein modified release matrix material comprises hydrophilic matrix material or hydrophobic matrix material or mixture thereof.
The extended release tablets according to claim 1, wherein the release is controlled by modified release coating material.
6. The extended release tablets according to claim 1, wherein the tablets comprises Capecitabine ranging from 150 to 750 mg. 7. Process for the preparation of extended release tablets according to claim
3, wherein the process comprises steps of:
a) Mixing Capecitabine, diluent(s) and modified release matrix material to form blend.
b) Preparing binder solution by dissolving binder into purified water. c) Granulating the blend obtained in step a) using binder solution. d) Mixing lubricant and / or glidant and optionally modified release matrix materials with granules obtained in step c).
e) Compressing the blended granules obtained in step d) to form tablets. f) Optionally, film coating the tablets obtained in step e.
8. Process for the preparation of extended release tablets according to claim 5, wherein the process comprises steps of:
a) Mixing Capecitabine and diluent.
b) Granulating the blend obtained in step a) using binder solution.
c) Mixing lubricant with granules obtained in step b).
d) Compressing the blended granules obtained in step c) to form tablets. e) Applying modified release coat on to the tablet obtained in step d).
9. Extended release tablets comprising
a) Capecitabine in an amount of 55 to 80 % w/w of the total weight of the tablet
b) Diluent in an amount of 1 to 15 % w/w of the total weight of the tablet
c) Modified release matrix material in an amount of 5 to 40 % w/w of the total weight of the tablet
d) Binder in an amount of 2 to 4 % w/w of the total weight of the tablet e) Lubricant in an amount of 0.5 to 2 % w/w of the total weight of the tablet.
10. Extended release tablets comprising
a) Capecitabine in an amount of 150 to 750 mg per tablet
b) Lactose in an amount of 5 to 35 mg per tablet
c) Microcrystalline cellulose in an amount of 5 to 50 mg per tablet d) Hydroxypropyl methylcellulose in an amount of 15 to 100 mg per tablet
e) Binder in an amount of 5 to 30 mg per tablet
2 f) Lubricant in an amount of 2 to 15 mg per tablet
wherein, the dissolution of Capecitabine from the tablets is 15 to 35% after 1 hour, 40 to 60% after 4 hours, 60 to 80% after 8 hours and not less than (NLT) 85% of the total amount of Capecitabine released after 12 hours.
3
PCT/IB2016/054780 2015-08-10 2016-08-09 Extended release capecitabine tablets WO2017025894A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3008MU2015 2015-08-10
IN3008/MUM/2015 2015-08-10

Publications (1)

Publication Number Publication Date
WO2017025894A1 true WO2017025894A1 (en) 2017-02-16

Family

ID=57983422

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/054780 WO2017025894A1 (en) 2015-08-10 2016-08-09 Extended release capecitabine tablets

Country Status (1)

Country Link
WO (1) WO2017025894A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013030602A1 (en) * 2011-09-02 2013-03-07 Slotervaart Participaties Bv Solid extended release composition for oral administration comprising substantially amorphous capecitabine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013030602A1 (en) * 2011-09-02 2013-03-07 Slotervaart Participaties Bv Solid extended release composition for oral administration comprising substantially amorphous capecitabine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PAVANI G. ET AL.: "Formulation and evaluation of capecitabine sustained release tablets;", INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACEUTICAL AND NANO SCIENCES., vol. 2, no. 6, 2013, pages 738 - 746, XP055363407 *

Similar Documents

Publication Publication Date Title
KR101156916B1 (en) Pharmaceutical compositions comprising imatinib and a release retardant
MX2010014566A (en) Melt granulation process.
JP2017222705A5 (en)
US20160193155A1 (en) Pulsatile-release dosage form
CN107920987A (en) Control delays to discharge Pregabalin
JP2011507973A (en) Pharmaceutical composition of amlodipine and valsartan
WO2006103551A1 (en) Controlled release formulations of oxycodone
EP2701689B1 (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
TW201427720A (en) Method for producing pharmaceutical preparation containing calcium antagonist/angiotensin ii receptor antagonist
EP3925601B1 (en) Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor
US20200054659A1 (en) Extended release capecitabine capsules
AU2016231883B2 (en) Pharmaceutical compositions of dimethyl fumarate
WO2017025894A1 (en) Extended release capecitabine tablets
JP6461142B2 (en) Anti-tuberculosis stable pharmaceutical composition in the form of a coated tablet containing isoniazid granules and rifapentine granules, and a process for producing the same
WO2018142359A1 (en) Composition comprising immediate release and extended release capecitabine
US20070298102A1 (en) Extended Release Pharmaceutical Composition of Celecoxib
EP3452054A1 (en) Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine
WO2008114276A1 (en) Novel oral controlled release composition of carvedilol
WO2023285977A1 (en) Pharmaceutical compositions of ozanimod
WO2020049429A1 (en) Novel composition of lapatinib of oral solid dosage form and method of manufacturing thereof
WO2015150948A1 (en) Modified release solid oral pharmaceutical compositions of cyclobenzaprine or a salt thereof
WO2013111147A1 (en) Extended release compositions of nevirapine
WO2014118721A1 (en) Pharmaceutical oral solid dosage forms comprising valsartan and nebivolol

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16834739

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16834739

Country of ref document: EP

Kind code of ref document: A1